抗体相关的各种联盟契约 - 契约条件、协定内容 (2014～2019年):资本交易趋势、企业、财务状况

本报告提供抗体相关的各种资本交易/事业联盟的契约缔结相关分析，近几年的各种契约的缔结趋势，及大规模契约及大医药品经营者的契约概要，各契约类型/各临床实验阶段/各技术/各治疗内容的契约一览等资讯彙整，为您概述为以下内容。

摘要整理

第1章 简介

第2章 抗体相关的各种交易趋势

• 简介
• 近几年的抗体相关的事业联盟数量
• 最活跃的，抗体相关的交易主体
• 抗体相关的事业联盟:各交易类型
• 抗体相关的事业联盟:各治疗领域
• 抗体相关的事业联盟:交易条件
  • 交易总额 (headline values)
  • 预付款金
  • 阶段性付款
  • 权利金费率

第3章 抗体相关的主要交易

• 简介
• 代表性资本交易 - 交易金额

第4章 抗体相关的最活跃的交易主体

• 简介
• 抗体相关的最活跃的交易主体
• 最活跃的交易主体:企业简介

第5章 抗体相关的契约缔结的一览

• 简介
• 签下的合约一览 (名录)

第6章 抗体相关的交易趋势:各技术种类

第7章 抗体相关的资源中心

• 抗体相关的联网数据库
• 抗体相关的活动/会议
• 抗体相关的参考文献

附录

• 附录 (1) - 抗体相关的资本交易:各企业 (ABC顺序)
• 附录 (2) - 抗体相关的资本交易:各临床实验阶段
  • 药物研发
  • 前临床
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 申请登记
  • 已上市
  • 剂型
• 附录 (3) - 抗体相关的资本交易:各交易类型
  • 资产购买
  • 权利转让
  • 大医药品企业的对外授权
  • 共同开发
  • 共同研究开发 (R&D)
  • 共同行销
  • 共同促销
  • CRADA (共同研究开发契约)
  • 交叉授权
  • 开发
  • 流通
  • 股票购买
  • 评估
  • 转让
  • 合资企业 (合资企业)
  • 授权
  • 贷款
  • 製造
  • 行销
  • 材料转移
  • 选择
  • 推销
  • 研究
  • 和解调停
  • 衍生公司
  • 再授权
  • 供给
  • 技术转移
  • 契约解除
• 附录 (4) - 抗体相关的资本交易:各治疗领域
  • 心血管
  • 中枢神经系统
  • 牙科
  • 皮肤科
  • 消化器官
  • 血液
  • 住院治疗
  • 免疫
  • 感染疾病
  • 代谢
  • 肌肉骨骼系统疾病
  • 产科
  • 肿瘤 (癌症)
  • 眼科
  • 罕见疾病
  • 小儿科
  • 精神科
  • 呼吸系统
• 附录 (5) - 资本交易的种类:定义

关于Wildwood Ventures

Description

Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of antibody deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1812 antibody deals announced since 2016 including financial terms where available including links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in antibody dealmaking since 2016.

Chapter 3 provides an overview of the leading antibody deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibody dealmaking with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse antibody collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Antibody Collaboration and Licensing Deals includes:

• Trends in antibody dealmaking in the biopharma industry
• Directory of antibody deal records covering pharmaceutical and biotechnology
• The leading antibody deals by value
• Most active antibody licensing dealmakers
• Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse antibody collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

• 2.1. Introduction
• 2.2. Antibody deals over the years
• 2.3. Most active antibody dealmakers
• 2.4. Antibody deals by deal type
• 2.5. Antibody deals by therapy area
• 2.6. Antibody deals by industry sector
• 2.7. Deal terms for antibody deals
  • 2.7.1 Antibody deals headline values
  • 2.7.2 Antibody deal upfront payments
  • 2.7.3 Antibody deal milestone payments
  • 2.7.4 Antibody royalty rates

Chapter 3 - Leading antibody deals

• 3.1. Introduction
• 3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers

• 4.1. Introduction
• 4.2. Most active antibody dealmakers
• 4.3. Most active antibody deals company profiles

Chapter 5 - Antibody contracts dealmaking directory

• 5.1. Introduction
• 5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

• Deal directory
• Deal directory - Antibody deals by company A-Z
• Deal directory - Antibody deals by deal type
• Deal directory - Antibody deals by therapy area
• Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering
•  

Table of figures

• Figure 1: Antibody deals since 2016
• Figure 2: Active antibody dealmaking activity - 2016 - 2023
• Figure 3: Antibody deals by deal type since 2016
• Figure 4: Antibody deals by therapy area since 2016
• Figure 5: Antibody deals by industry sector since 2016
• Figure 6: Antibody deals with a headline value
• Figure 7: Antibody deals with an upfront value
• Figure 8: Antibody deals with a milestone value
• Figure 9: Antibody deals with a royalty rate value
• Figure 10: Top antibody deals by value since 2016
• Figure 11: Most active antibody dealmakers 2016 - 2023
• Figure 12: Antibody deals by technology type since 2016